Claims
- 1. The process for producing a smooth muscle relaxant effect in a mammal which comprises administering thereto a non-toxic dose of from about 0.01 to 10 mg./kg. of body weight of said mammal of a compound selected from the group consisting of 10-imidoylphenoxazines having the formula ##STR5## and a non-toxic pharmaceutically acceptable acid addition salt thereof wherein
- X represents oxygen
- Y represents hydrogen, trifluoromethyl, halogen, dihalogen, lower alkyl of 1 to 4 carbon atoms inclusive, lower alkoxy of 1to 4 carbon atoms inclusive; and
- A is selected from the group consisting of ##STR6## wherein R.sub.1 is lower alkyl of 1 to 4 carbon atoms inclusive or cycloalkyl of 3 to 6 carbon atoms inclusive;
- R.sub.2 is hydrogen or lower alkyl of 1 to 4 carbon atoms inclusive;
- R.sub.3 and R.sub.4 are independent members selected from the group consisting of hydrogen or lower alkyl of 1 to 4 carbon atoms inclusive;
- n is an integer of 3 to 5.
- 2. The process of claim 1 wherein said compound is 10-(1-pyrrolin-2-yl)phenoxazine or a pharmaceutically acceptable non-toxic acid addition salt thereof.
- 3. The process of claim 1 wherein said compound is 10-(5-methyl-1-pyrrolin-2-yl)phenoxazine or a pharmaceutically acceptable non-toxic acid addition salt thereof.
- 4. The process of claim 1 wherein said compound is 10-(5,5-dimethyl-1-pyrrolin-2-yl)phenoxazine or a pharmaceutically acceptable non-toxic acid addition salt thereof.
- 5. The process of claim 1 wherein said compound is 10-(1-pyrrolin-2-yl)-2-(trifluoromethyl)phenoxazine or a pharmaceutically acceptable non-toxic acid addition salt thereof.
- 6. The process of claim 1 wherein said compound is 10-(5-methyl-1-pyrrolin-2-yl)-2-(trifluoromethyl)phenoxazine or a pharmaceutically acceptable non-toxic acid addition salt thereof.
- 7. The process of claim 1 wherein said compound is 1.UPSILON.-(5,5-dimethyl-1-pyrrolin-2-yl)-2-(trifluoromethyl)phenoxazine or a pharmaceutically acceptable non-toxic acid addition salt thereof.
- 8. The process of claim 1 wherein said compound is 2-chloro10-(1-pyrrolin-2-yl)phenoxazine or a pharmaceutically acceptable non-toxic acid addition salt thereof.
- 9. The process of claim 1 wherein said compound is 2-chloro-10-(5-methyl-1-pyrrolin-2-yl)phenoxazine or a pharmaceutically acceptable non-toxic acid addition salt thereof.
- 10. The process of claim 1 wherein said compound is 2-chloro-10-(5,5-dimethyl-1-pyrrolin-2-yl)phenoxazine or a pharmaceutically acceptable non-toxic acid addition salt thereof.
- 11. The process of claim 1 wherein said compound is 4-chloro-10-(5-methyl-1-pyrrolin-2-yl)phenoxoazine or a pharmaceutically acceptable non-toxic acid addition salt thereof.
- 12. The process of claim 1 wherein said compound is 2-methoxy-10-(5-methyl-1-pyrrolin-2-yl)phenoxazine or a pharmaceutically acceptable non-toxic acid addition salt thereof.
- 13. The process of claim 1 wherein said compound is 10-(3,4,5,6-tetrahydro-2-pyridyl)phenoxazine or a pharmaceutically acceptable non-toxic acid addition salt thereof.
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a divisional of co-pending application Ser. No. 561,462, filed Mar. 24, 1975, and now U.S. Pat. No. 3,962,252 which in turn is a division of then co-pending application Ser. No. 336,671, filed Feb. 28, 1973, and now U.S. Pat. No. 3,888,852.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
3719671 |
Wu et al. |
Mar 1973 |
|
Divisions (2)
|
Number |
Date |
Country |
Parent |
561462 |
Mar 1975 |
|
Parent |
336671 |
Feb 1973 |
|